Plasma matrix metalloproteinases 7 and 9 in patients with metastatic breast cancer treated with marimastat or placebo

Eastern cooperative oncology group trial E2196

Stanley Zucker, Molin Wang, Joseph A. Sparano, William J. Gradishar, James N. Ingle, Nancy E. Davidson

Research output: Contribution to journalArticle

Abstract

Background: The purpose of this study was to evaluate the prognostic and predictive utility of measuring plasma levels of matrix metalloproteinase (MMP)-7 and MMP-9 in patients with metastatic breast cancer (MBC) treated with the oral MMP inhibitor (MMPI) marimastat or a placebo. Patients and Methods: We measured plasma levels of MMP-7 and M MP-9 using an enzyme-linked immunoassay method in 140 evaluable patients with MBC enrolled on a multicenter clinical trial that compared the MMPI marimastat with placebo. Specimens were collected after completion of first-line chemotherapy in patients who had responding or stable disease and 3, 6, and 12 months after initiation of marimastat (10 mg orally twice daily) or placebo. Results: Baseline plasma MMP-7 and MMP-9 level s did not correlate with each other or with progression-free or overall survival. In addition, serial evaluation of plasma MMP-7 and MMP-9 levels revealed no significant changes over time in the marimastat or placebo groups or any correlation with trough plasma marimastat level. Conclusion: We conclude that measurement of plasma MMP-7 or MMP-9 levels, as performed in our trial, was not a useful prognostic or predictive factor in patients with MBC or in patients treated with an MMPI.

Original languageEnglish (US)
Pages (from-to)525-529
Number of pages5
JournalClinical Breast Cancer
Volume6
Issue number6
DOIs
StatePublished - 2006

Fingerprint

Matrix Metalloproteinase 7
Matrix Metalloproteinase 9
Placebos
Breast Neoplasms
Matrix Metalloproteinase Inhibitors
Immunoenzyme Techniques
Multicenter Studies
marimastat
Clinical Trials
Drug Therapy
Survival

Keywords

  • Matrix metalloproteinase inhibitors
  • Phase III trials
  • Survival

ASJC Scopus subject areas

  • Cancer Research

Cite this

Plasma matrix metalloproteinases 7 and 9 in patients with metastatic breast cancer treated with marimastat or placebo : Eastern cooperative oncology group trial E2196. / Zucker, Stanley; Wang, Molin; Sparano, Joseph A.; Gradishar, William J.; Ingle, James N.; Davidson, Nancy E.

In: Clinical Breast Cancer, Vol. 6, No. 6, 2006, p. 525-529.

Research output: Contribution to journalArticle

Zucker, Stanley ; Wang, Molin ; Sparano, Joseph A. ; Gradishar, William J. ; Ingle, James N. ; Davidson, Nancy E. / Plasma matrix metalloproteinases 7 and 9 in patients with metastatic breast cancer treated with marimastat or placebo : Eastern cooperative oncology group trial E2196. In: Clinical Breast Cancer. 2006 ; Vol. 6, No. 6. pp. 525-529.
@article{2595e7e787f24699b2987a2b1bdf54ab,
title = "Plasma matrix metalloproteinases 7 and 9 in patients with metastatic breast cancer treated with marimastat or placebo: Eastern cooperative oncology group trial E2196",
abstract = "Background: The purpose of this study was to evaluate the prognostic and predictive utility of measuring plasma levels of matrix metalloproteinase (MMP)-7 and MMP-9 in patients with metastatic breast cancer (MBC) treated with the oral MMP inhibitor (MMPI) marimastat or a placebo. Patients and Methods: We measured plasma levels of MMP-7 and M MP-9 using an enzyme-linked immunoassay method in 140 evaluable patients with MBC enrolled on a multicenter clinical trial that compared the MMPI marimastat with placebo. Specimens were collected after completion of first-line chemotherapy in patients who had responding or stable disease and 3, 6, and 12 months after initiation of marimastat (10 mg orally twice daily) or placebo. Results: Baseline plasma MMP-7 and MMP-9 level s did not correlate with each other or with progression-free or overall survival. In addition, serial evaluation of plasma MMP-7 and MMP-9 levels revealed no significant changes over time in the marimastat or placebo groups or any correlation with trough plasma marimastat level. Conclusion: We conclude that measurement of plasma MMP-7 or MMP-9 levels, as performed in our trial, was not a useful prognostic or predictive factor in patients with MBC or in patients treated with an MMPI.",
keywords = "Matrix metalloproteinase inhibitors, Phase III trials, Survival",
author = "Stanley Zucker and Molin Wang and Sparano, {Joseph A.} and Gradishar, {William J.} and Ingle, {James N.} and Davidson, {Nancy E.}",
year = "2006",
doi = "10.3816/CBC.2006.n.006",
language = "English (US)",
volume = "6",
pages = "525--529",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Plasma matrix metalloproteinases 7 and 9 in patients with metastatic breast cancer treated with marimastat or placebo

T2 - Eastern cooperative oncology group trial E2196

AU - Zucker, Stanley

AU - Wang, Molin

AU - Sparano, Joseph A.

AU - Gradishar, William J.

AU - Ingle, James N.

AU - Davidson, Nancy E.

PY - 2006

Y1 - 2006

N2 - Background: The purpose of this study was to evaluate the prognostic and predictive utility of measuring plasma levels of matrix metalloproteinase (MMP)-7 and MMP-9 in patients with metastatic breast cancer (MBC) treated with the oral MMP inhibitor (MMPI) marimastat or a placebo. Patients and Methods: We measured plasma levels of MMP-7 and M MP-9 using an enzyme-linked immunoassay method in 140 evaluable patients with MBC enrolled on a multicenter clinical trial that compared the MMPI marimastat with placebo. Specimens were collected after completion of first-line chemotherapy in patients who had responding or stable disease and 3, 6, and 12 months after initiation of marimastat (10 mg orally twice daily) or placebo. Results: Baseline plasma MMP-7 and MMP-9 level s did not correlate with each other or with progression-free or overall survival. In addition, serial evaluation of plasma MMP-7 and MMP-9 levels revealed no significant changes over time in the marimastat or placebo groups or any correlation with trough plasma marimastat level. Conclusion: We conclude that measurement of plasma MMP-7 or MMP-9 levels, as performed in our trial, was not a useful prognostic or predictive factor in patients with MBC or in patients treated with an MMPI.

AB - Background: The purpose of this study was to evaluate the prognostic and predictive utility of measuring plasma levels of matrix metalloproteinase (MMP)-7 and MMP-9 in patients with metastatic breast cancer (MBC) treated with the oral MMP inhibitor (MMPI) marimastat or a placebo. Patients and Methods: We measured plasma levels of MMP-7 and M MP-9 using an enzyme-linked immunoassay method in 140 evaluable patients with MBC enrolled on a multicenter clinical trial that compared the MMPI marimastat with placebo. Specimens were collected after completion of first-line chemotherapy in patients who had responding or stable disease and 3, 6, and 12 months after initiation of marimastat (10 mg orally twice daily) or placebo. Results: Baseline plasma MMP-7 and MMP-9 level s did not correlate with each other or with progression-free or overall survival. In addition, serial evaluation of plasma MMP-7 and MMP-9 levels revealed no significant changes over time in the marimastat or placebo groups or any correlation with trough plasma marimastat level. Conclusion: We conclude that measurement of plasma MMP-7 or MMP-9 levels, as performed in our trial, was not a useful prognostic or predictive factor in patients with MBC or in patients treated with an MMPI.

KW - Matrix metalloproteinase inhibitors

KW - Phase III trials

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=33645642050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645642050&partnerID=8YFLogxK

U2 - 10.3816/CBC.2006.n.006

DO - 10.3816/CBC.2006.n.006

M3 - Article

VL - 6

SP - 525

EP - 529

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 6

ER -